Myasthenia Gravis

Approximately 70 to 300 million individuals worldwide are living with myasthenia gravis, an antibody-mediated autoimmune disorder that adversely affects neuromuscular junction function.

Patient acceptable symptom state (PASS) may be a reliable indicator of long-term outcomes among patients who have myasthenia gravis (MG).

The highest proportions of patients with severe ocular impairment at baseline showed greater improvements in symptom severity on ravulizumab in comparison with placebo after 26 weeks.

The investigation evaluated if symptom signatures of myasthenia gravis exacerbations could be evaluated using real-world data gathered via a smartphone-based research platform.

With this study, investigators hoped to describe personality traits among individuals who have the autoimmune, neuromuscular disease.

Investigators say computer algorithms can be used to assess physical and vocal signs of myasthenia gravis (MG).

This study compared autoantigen detection of acetylcholine receptor and muscle-specific kinase, among 3 assays used in suspected cases of myasthenia gravis.

Study authors used data from the Taiwan National Healthcare Insurance Research database and Death Registry for their population-based retrospective cohort study.

Nearly half of patients treated with zilucoplan were considered responders on Myasthenia Gravis Activities of Daily Living (MG-ADL) at the first week, suggesting a rapid onset of efficacy.

Investigators conducted a case study of a patient who presented with COVID-19–induced seronegative myasthenia gravis, seeking more information on neurological manifestations of the respiratory disease.

Lymphoplasmapheresis (LPE) was also completed with fewer replacements compared with plasma exchange (PE) for myasthenia gravis (MG).

The patient was found to have Toxoplasma gondii, a parasitic infection, and died 5 months after his initial diagnosis.

However, few patients with nonthymomatous myasthenia gravis (NTMG) undergo this procedure, results suggest.

A real-world study of 5 European countries shows frequent misdiagnoses/delays in diagnosis, acute hospitalizations, and quality-of-life impairments.

The patient in this case experienced significant muscle weakness after emerging from anesthesia.

The rare autoimmune disorder generalized myasthenia gravis can cause muscle weakness in the limbs and face.

The treatment is the first approved by the FDA to treat the 2 most common subtypes of generalized myasthenia gravis.

Future myasthenia gravis therapies have different mechanisms of action than current treatments, said James F. Howard Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill.

James F. Howard Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill, explains how nerve and muscle signaling in the neuromuscular junction go awry in myasthenia gravis.

Both complement inhibitors and neonatal Fc receptor blockers led to improvements in symptoms, according to a meta-analysis.

The scale is meant to better quantify how clusters of symptoms impact patients’ quality of life.

Unmet needs include both improved myasthenia gravis treatments as well as a way to monitor progression of the disease, said James F. Howard, Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill.

Current myasthenia gravis therapies can exacerbate comorbidities or create other complications, said James F. Howard Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill.

The majority of respondents living with generalized myasthenia gravis (MG) were not working, the results showed.

Myasthenia gravis expert James F. Howard, Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill, explains the burdens that step therapy places on patients with rare diseases and their providers.